![Matthew Norkunas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Norkunas
Directeur/Membre du Conseil chez
Obsidian Therapeutics, Inc.
Fortune : 541 707 $ au 31/08/2026
Profil
Matthew Norkunas currently works at Obsidian Therapeutics, Inc., as Director from 2023 and Obsidian Therapeutics, Inc., as Director from 2026.
Dr. Norkunas also formerly worked at Marsico Capital Management LLC, as Research Analyst from 2012 to 2013, SomaLogic Operating Co., Inc., as Chief Financial Officer from 2016 to 2020, and Generation Bio Co., as Chief Financial & Accounting Officer.
Dr. Norkunas received his undergraduate degree in 1999 from St. Mary's College (Maryland), doctorate degree from the University of Maryland School of Medicine, and Masters Business Admin degree from Columbia Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,05% | 03/08/2026 | 30 937 ( 0,05% ) | 541 707 $ | 31/08/2026 |
Postes actifs de Matthew Norkunas
| Sociétés | Poste | Début |
|---|---|---|
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Directeur/Membre du Conseil | 23/05/2023 |
Anciens postes connus de Matthew Norkunas
| Sociétés | Poste | Fin |
|---|---|---|
| GENERATION BIO CO. | Directeur Financier/CFO | 10/01/2025 |
SomaLogic Operating Co., Inc.
 SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology Operates as a protein biomarker discovery and clinical diagnostics company | Directeur Financier/CFO | 01/06/2020 |
Marsico Capital Management LLC
 Marsico Capital Management LLC Investment ManagersFinance MCM seeks to combine the early identification of long-term secular themes with rigorous fundamental research to identify high-quality companies with exceptional long-term growth potential. The firm blends top-down macroeconomic analysis and theme development with bottom-up stock selection. | Analyst-Equity | - |
Formation de Matthew Norkunas
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Marsico Capital Management LLC
Marsico Capital Management LLC Investment ManagersFinance MCM seeks to combine the early identification of long-term secular themes with rigorous fundamental research to identify high-quality companies with exceptional long-term growth potential. The firm blends top-down macroeconomic analysis and theme development with bottom-up stock selection. | Finance |
St. Mary's College (Maryland)
 St. Mary's College (Maryland) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology Operates as a protein biomarker discovery and clinical diagnostics company | Health Technology |
University of Maryland School of Medicine
 University of Maryland School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Health Technology |
Generation Bio Co.
 Generation Bio Co. Pharmaceuticals: MajorHealth Technology Develops and commercializes genetic medicines | Health Technology |
